Mostrar registro simples

dc.contributor.advisorSfair, Letícia Lenzpt_BR
dc.contributor.authorCarvalho, Anelise Miglioranza dept_BR
dc.date.accessioned2016-04-23T02:06:55Zpt_BR
dc.date.issued2011pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/139376pt_BR
dc.description.abstractGlaucoma is an optic neuropathy caused by multiple factors, characterized by progressive damage to the optic nerve and increased intraocular pressure, its main risk factor. Brinzolamide is a sulfonamide nonbacteriostatic derivative inhibitor of carbonic anhydrase II, which decreases the intraocular pressure by reducing aqueous humor formation. A stability-indicating HPLC method for the determination of brinzolamide in ophthalmic solution was developed and validated. Chromatographic analysis were performed in Phemomenex® C18 column (150x4.6 mm, particle size 5 μm). The mobile phase was composed of acetonitrile and 25 mM monobasic potassium phosphate buffer adjusted to pH 5.8 (40:60; v/v), flow rate of 1.0 mL/min and injection volume of 20 μL. The method was simple, rapid, specific, linear, precise, accurate and robust, suitable for use in routine quality control.en
dc.format.mimetypeapplication/pdf
dc.language.isoporpt_BR
dc.rightsOpen Accessen
dc.subjectBrinzolamideen
dc.subjectBrinzolamidapt_BR
dc.subjectSuspensões oftálmicaspt_BR
dc.subjectMethod validationen
dc.subjectStability-indicating methoden
dc.subjectValidação : Métodos de análise de fármacospt_BR
dc.titleDesenvolvimento e validação de método analítico para determinação de brinzolamida em suspensão oftálmica 1%pt_BR
dc.typeTrabalho de conclusão de graduaçãopt_BR
dc.contributor.advisor-coSteppe, Martinpt_BR
dc.identifier.nrb000865990pt_BR
dc.degree.grantorUniversidade Federal do Rio Grande do Sulpt_BR
dc.degree.departmentFaculdade de Farmáciapt_BR
dc.degree.localPorto Alegre, BR-RSpt_BR
dc.degree.date2011pt_BR
dc.degree.graduationFarmáciapt_BR
dc.degree.levelgraduaçãopt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples